Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2026)

Mimedx's Asset Writedowns and Impairment history spans 10 years, with the latest figure at $1.5 million for Q1 2026.

On a quarterly basis, Asset Writedowns and Impairment rose 97.3% to $1.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.2 million, a 536.5% increase, with the full-year FY2025 number at $6.5 million, up 994.96% from a year prior.
Asset Writedowns and Impairment hit $1.5 million in Q1 2026 for Mimedx, down from $3.4 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for MDXG hit a ceiling of $3.4 million in Q4 2025 and a floor of -$279000.0 in Q3 2024.
Historically, Asset Writedowns and Impairment has averaged $834687.5 across 5 years, with a median of $436500.0 in 2022.
Biggest five-year swings in Asset Writedowns and Impairment: surged 48200.0% in 2023 and later crashed 162.42% in 2024.
Tracing MDXG's Asset Writedowns and Impairment over 5 years: stood at $3000.0 in 2022, then surged by 48200.0% to $1.4 million in 2023, then tumbled by 68.67% to $454000.0 in 2024, then surged by 641.41% to $3.4 million in 2025, then tumbled by 56.51% to $1.5 million in 2026.
Business Quant data shows Asset Writedowns and Impairment for MDXG at $1.5 million in Q1 2026, $3.4 million in Q4 2025, and $2.1 million in Q3 2025.